190 related articles for article (PubMed ID: 21562302)
1. New therapeutic options: management strategies to optimize glycemic control.
Sisam DA
J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
[No Abstract] [Full Text] [Related]
2. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
Seufert J
Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
[TBL] [Abstract][Full Text] [Related]
3. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
4. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
5. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
6. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
7. Insulin initiation in Type 2 diabetes.
Page S
Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
[No Abstract] [Full Text] [Related]
8. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of intensive glucose control in type 2 diabetes.
Lund SS; Rossing P; Vaag AA
N Engl J Med; 2009 Jan; 360(4):416; author reply 418. PubMed ID: 19164195
[No Abstract] [Full Text] [Related]
10. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of intensive glucose control in type 2 diabetes.
Mühlhauser I
N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
[No Abstract] [Full Text] [Related]
14. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
15. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
16. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
[TBL] [Abstract][Full Text] [Related]
17. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Holloway AC; Hettinga BP; Gerstein HC
J Diabetes; 2011 Mar; 3(1):74-81. PubMed ID: 21040499
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng CH; Huang TS
Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
[No Abstract] [Full Text] [Related]
19. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
[TBL] [Abstract][Full Text] [Related]
20. beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S; Bianchi C; Marchetti P
Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
